Blog Voices from the Frontlines
International Medical Cannabis Advocates Address WHO Committee to Reschedule Cannabis - Americans for Safe Access
This week medical cannabis patient advocacy groups from Argentina, Mexico, Uruguay, France, Germany, New Zealand, the Netherlands, South Africa, and the United States travelled to Geneva, Switzerland to present to world leaders their recommendations for rescheduling cannabis at the 40th meeting of the World Health Organization's (WHO) Expert Committee on Drug Dependence (ECDD).
The air was filled with excitement that the ECDD was finally beginning the process of looking at new information regarding cannabis as medicine. A process that has been long overdue considering the original scheduling of cannabis was created based on a report produced by the Health Committee of the League of Nations back in 1935. International bodies have been calling on the WHO to address the scheduling of cannabis for almost a decade, and the WHO finally listened.
Contact your Senators and Representative today to ask them to ensure the CJS Medical Marijuana Amendment is included in the FY2018 appropriations package AND end the federal conflict once and for all by sponsoring the CARERS Act.
International Medical Cannabis Advocates Address WHO Committee Set to Advise UN
Geneva, Switzerland — Yesterday, Americans for Safe Access (ASA), along with members of the International Medical Cannabis Patients Coalition (IMCPC), attended and delivered testimony at the 40th meeting of the World Health Organization's (WHO) Expert Committee on Drug Dependence (ECDD) being held in Geneva, Switzerland, June 4-7th, 2018.
In a milestone moment for medical cannabis patients, the ECDD will be reviewing and assessing the medical uses and harms of Cannabis, in order to recommend the most appropriate classification to be applied internationally. The agenda of the meeting is dedicated to carrying out pre-reviews of cannabis and cannabis-related substances. Members of ASA and IMCPC produced and delivered 1 Critical Review and 3 Pre-Review reports on Cannabidiol (CBD), Cannabis plant and cannabis resin, Extracts and tinctures of cannabis, and Delta-9-tetrahydrocannabinol (THC), which included references and recommendations for the committee to use in their review.
By Christopher Moraff for The Daily Beast
Dr. Jahan Marcu, Senior Scientist at Americans for Safe Access, a marijuana advocacy group, calls the reemergence of synthetic cannabinoids a “product safety nightmare.”
“It’s like ordering a drink and not knowing if it’s 0 percent alcohol or full proof,” he said.
By Jonathan D. Salant for NJ.Com
"Public opinion is changing on this issue," said Rep. Matt Gaetz, R-Fla., the chief sponsor of the Medical Cannabis Research Act, which authorizes research into the medical benefits of marijuana. "Congress is behind. We need to catch up.
"Two pro-marijuana groups, the National Cannabis Industry Association and Americans for Safe Access, held press conferences and met with federal lawmakers on Capitol Hill.
Medical Cannabis Patients, Medical Professionals, Advocates, and Industry Leaders Converge at National Medical Cannabis Unity Conference in D.C. - Americans for Safe Access
May 22 - May 25, 2018
Contact: Debbie Churgai | 202-857-4272 x.8 | email@example.com
WASHINGTON, DC — Starting on Tuesday, May 22nd and running until Friday, May 25th, medical cannabis patients, advocates, medical and legal professionals, and industry business leaders will gather at Americans for Safe Access’ (ASA) Annual National Medical Cannabis Unity conference in Washington, D.C. to learn and exchange ideas about how to navigate and steer medical cannabis policy in this ever-changing political landscape.
What: 6th Annual National Medical Cannabis Unity Conference
Where: Omni Shoreham Hotel in Washington, DC,
When: Tuesday, May 22nd through Friday, May 25th
This year's conference will focus on the life-saving role that medical cannabis can play in the fight against the Opioid Epidemic. In 2017 ASA launched the End Pain, Not Lives campaign, to help protect current medical cannabis programs, remove barriers for people with pain, chronic pain, and Opioid Use Disorder, and to educate medical professionals, service providers, and patients about medical cannabis and pain.
By Herbert Fuego for Westword
Most people thought the fight was over when Colorado voters legalized commercial cannabis in 2012, but that victory led to a series of smaller battles over such issues as social consumption, home-grow limitations and industry expansion. Proposals continue to pop up on both the local and state level that could advance or limit your rights as a cannabis consumer, patient, grower or business owner. Want to make sure things go in the right direction? Here's how to become a cannabis advocate:
By Taryn Luna for The Sacramento Bee
There's a problem with access to legal weed in California, and a Senate bill may help solve it.
A 2016 voter-approved measure to legalize marijuana in the state gave cities and counties the authority to pass regulations outlining the types of weed businesses that can operate within their borders. With limited time to craft rules before the law took effect at the start of the year, many towns approved outright bans of all marijuana businesses.
In the May 2018 Issue:
- ASA’s National Unity Conference Starts May 22
- ASA Submits Guidance to FDA for International Rescheduling
- Three States Expand Medical Cannabis Programs
- Voters in Oklahoma and Utah to Decide Safe Access
- Activist Profile: Jennifer Collins, Virginia
- ACTION ALERT: Join ASA in Lobbying Congress on May 23
By Jon O'Connell for The Citizens' Voice
Pennsylvania’s newest industry comes with a learning curve.
More than 7,000 people now carry medical marijuana ID cards to treat illness with cannabis, and thousands more seek them. However, it remains a legal conundrum when it comes to federal law, and it’s still disparaged as weak science by some physicians. Uninformed patients risk getting frustrated or giving up without the right resources.
During the first hour of the Cannabis Learn conference Monday in Philadelphia, Jahan Marcu, Ph.D., chief scientific officer with Americans for Safe Access, and the organization’s associate director, Debbe Churgai, offered some starting guidelines for patients and their caregivers considering cannabis as a treatment option.